Mediclinic International PLC (MDC) Receives Average Rating of “Hold” from Brokerages
Mediclinic International PLC (LON:MDC) has been assigned a consensus rating of “Hold” from the seven ratings firms that are covering the stock, Marketbeat.com reports. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is GBX 645.17 ($8.32).
A number of analysts recently commented on MDC shares. Barclays dropped their price target on shares of Mediclinic International from GBX 751 ($9.69) to GBX 700 ($9.03) and set an “overweight” rating on the stock in a research note on Tuesday, August 7th. Credit Suisse Group dropped their price target on shares of Mediclinic International from GBX 660 ($8.51) to GBX 550 ($7.09) and set a “neutral” rating on the stock in a research note on Thursday, August 9th.
Shares of MDC stock opened at GBX 493.10 ($6.36) on Friday. Mediclinic International has a 12 month low of GBX 495.40 ($6.39) and a 12 month high of GBX 890.18 ($11.48).
Mediclinic International plc, together with its subsidiaries, operates private hospitals. The company offers acute care, specialist-orientated, and multidisciplinary healthcare services under the Mediclinic and Hirslanden brand names. It operates 17 private acute care hospitals and 4 clinics with approximately 1,805 inpatient beds in Switzerland; 49 acute care private hospitals and 2 day clinics in South Africa, and 3 hospitals in Namibia with approximately 8,131 inpatient beds; and 6 acute care private hospitals and 22 clinics with approximately 748 inpatient beds in the United Arab Emirates.
Recommended Story: Technical Analysis
Receive News & Ratings for Mediclinic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediclinic International and related companies with MarketBeat.com's FREE daily email newsletter.